Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + cisplatin + docetaxel + etoposide
- Development stage
- Phase 2
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination chemotherapy regimen consisting of four agents—bevacizumab, cisplatin, docetaxel, and etoposide—used primarily in the treatment of unresectable stage III non-small cell lung cancer (NSCLC). Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), thereby blocking angiogenesis and reducing tumor blood supply. Cisplatin is a platinum-based chemotherapeutic agent that forms DNA crosslinks and induces apoptosis. Docetaxel is a taxane-class antineoplastic that stabilizes microtubules, inhibiting cell division. Etoposide inhibits topoisomerase II, leading to DNA strand breaks and apoptosis. This combination has been investigated in clinical trials for its efficacy and safety profile when used with or without concurrent radiotherapy in NSCLC patients[2][5][8]. The regimen aims to maximize cytotoxic effects on tumor cells through multiple mechanisms while also targeting the tumor vasculature.
- Other names
- Bevacizumab, docetaxel, cisplatinBevacizumab + Docetaxel + Cisplatin
02
Targets
DNATOP2A (DNA topoisomerase II)TOP2B (DNA topoisomerase II beta)VEGFA (Vascular endothelial growth factor A)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on bevacizumab + cisplatin + docetaxel + etoposide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + cisplatin + docetaxel + etoposide.